Free Trial
NASDAQ:ENTX

Entera Bio Q3 2023 Earnings Report

Entera Bio logo
$1.96 +0.03 (+1.29%)
As of 10:10 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Entera Bio EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.09
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Entera Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Entera Bio Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Entera Bio's Q3 2025 earnings is scheduled for Friday, November 14, 2025, with a conference call scheduled on Friday, November 7, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Entera Bio Earnings Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Entera Bio Beats Q2 EPS Estimates
See More Entera Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Entera Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entera Bio and other key companies, straight to your email.

About Entera Bio

Entera Bio (NASDAQ:ENTX), a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

View Entera Bio Profile

More Earnings Resources from MarketBeat